Prior art

Prior Art Analysis for US Patent 11,021,437

The following analysis details the most relevant prior art cited against US Patent 11,021,437, focusing on potential anticipation of the claimed subject matter under 35 U.S.C. § 102. The analysis is based on the citations listed in the patent's file wrapper.

Patent Citations

1. US Patent 3,809,714 A ("Hussain '714")

• Full Citation: US Patent 3,809,714, "Novel ester of ((methylamino)methyl) benzyl alcohol," filed by Anwar A. Hussain and James E. Truelove.
• Publication/Filing Dates: Publication Date: May 7, 1974; Filing Date: August 31, 1972.
• Brief Description: The '714 patent discloses novel di-esters of epinephrine, specifically created to be prodrugs with increased lipid solubility. The stated purpose is to enhance penetration through the cornea for the treatment of glaucoma. The patent explicitly describes several compounds that are ester derivatives of epinephrine, including 4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylene diacetate (Structure 7A in the '437 patent), 4-(1-hydroxy-2(methylamino)ethyl)-1,2-phenylene bis(2-methylpropanoate) (Structure 7B), and 4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylene dipropionate (Structure 7C). The '437 patent itself acknowledges this prior work by Hussain and Truelove.
• Potential Anticipation:
  • Claim 2: This claim is directed to a compound of a specific formula where R is selected from CH₃, CH₂CH₃, and CH(CH₃)₂. The compounds disclosed in the Hussain '714 patent, such as the diacetate (R=CH₃), dipropionate (R=CH₂CH₃), and the bis(2-methylpropanoate) (R=CH(CH₃)₂), appear to fall directly within the scope of this claim.
  • Claim 3: This claim recites a group of specific compounds, all of which are explicitly taught in the Hussain '714 patent. Therefore, this claim appears to be anticipated by the '714 patent.
  • The '714 patent focuses on ophthalmic use, not sublingual or buccal delivery in a rapidly dissolving film. Therefore, it would not, on its own, anticipate claims that require this specific dosage form and administration route, such as claims 1 and 5.

2. US Patent 3,825,583 A ("Hussain '583")

• Full Citation: US Patent 3,825,583, "Ester of 3-hydroxy-alpha-((methylamino)methyl)benzyl alcohol," filed by Anwar A. Hussain and James E. Truelove.
• Publication/Filing Dates: Publication Date: July 23, 1974; Filing Date: April 26, 1973.
• Brief Description: This patent is also from Hussain and Truelove and is related to the '714 patent. It discloses mono-ester prodrugs of epinephrine, where only one of the hydroxyl groups on the benzene ring is esterified. The goal, similar to the '714 patent, was to improve properties for ophthalmic delivery.
• Potential Anticipation: The claims of the '437 patent are directed to di-esters, where both hydroxyl groups are modified. As the '583 patent discloses mono-esters, it does not directly anticipate the claimed compounds. However, it establishes the state of the art regarding the creation of epinephrine ester prodrugs for improved drug delivery.

3. US Patent 4,136,145 A ("Fuchs")

• Full Citation: US Patent 4,136,145, "Medicament carriers in the form of film having active substance incorporated therein," filed by Fuchs, et al.
• Publication/Filing Dates: Publication Date: January 23, 1979; Filing Date: July 5, 1974.
• Brief Description: The Fuchs patent discloses the concept of incorporating a pharmaceutically active ingredient into a rapidly dissolving film for application to mucosal membranes, including the mouth. The '437 patent explicitly mentions this reference in its "Description of Related Art" section.
• Potential Anticipation:
  • This patent teaches the delivery vehicle (a rapidly dissolving film for mucosal administration) recited in several of the '437 patent's claims (e.g., claims 1, 2, 3, and 5). However, Fuchs does not specifically disclose the use of epinephrine or its prodrugs in these films. Therefore, Fuchs alone would not anticipate any of the claims. Its relevance is more significant in an obviousness analysis (35 U.S.C. § 103), where it could be combined with prior art that teaches the claimed epinephrine prodrugs.

4. US Patent Application Publication 2007/0202163 A1 ("Rawas-Qalaji")

• Full Citation: US Patent Application Publication 2007/0202163, "Fast-disintegrating epinephrine tablets for buccal or sublingual administration."
• Publication/Filing Dates: Publication Date: August 30, 2007; Filing Date: September 9, 2005.
• Brief Description: Rawas-Qalaji discloses fast-disintegrating tablets of epinephrine for sublingual or buccal administration as an alternative to injection for treating anaphylaxis. The '437 patent cites a 2006 study by Rawas-Qalaji et al. that demonstrated dose bioequivalence between a 40 mg sublingual epinephrine tablet and a 0.3 mg intramuscular injection.
• Potential Anticipation: This reference teaches the sublingual/buccal administration of epinephrine in a fast-disintegrating dosage form for treating anaphylaxis. It does not, however, disclose the specific epinephrine prodrugs claimed in the '437 patent, nor does it specifically mention a film as the dosage form. Therefore, it would not anticipate the claims but is highly relevant to the field of the invention and would be a key reference in an obviousness argument. It teaches the motivation to develop non-injectable, rapid-acting epinephrine formulations for anaphylaxis.